COMMON STOCK |
3 Months Ended |
|---|---|
Mar. 31, 2025 | |
| Equity [Abstract] | |
| COMMON STOCK | 7. COMMON STOCK
At March 31, 2025, the Company's authorized capital stock was shares of common stock, par value $ per share, and shares of preferred stock, par value $ per share. On that date, the Company had shares of common stock issued and shares of common stock outstanding. There were shares of preferred stock outstanding.
Stock-based compensation expense related to Company grants for the three months ended March 31, 2025 and 2024 was $ and $, respectively.
2025 Transactions – During the three months ended March 31, 2025, the Company issued shares of common stock for vested stock awards and the exercise of stock options. No stock options were exercised.
The Company also granted restricted stock awards during the three months ended March 31, 2025. For the stock awards granted, the weighted average grant date fair value was $ and vest over a period of .
2024 Transactions – During the three months ended March 31, 2024, the Company issued shares of common stock for vested stock awards and the exercise of stock options. No stock options were exercised.
The Company also granted restricted stock awards during the three months ended March 31, 2024. For the stock awards granted, the weighted average grant date fair value was $ and vest over a period of .
|